PubMed Health⌕ Search

PubMed · 12486752

Improved up-and-down designs for phase I trials.

Abstract

We consider several designs from the family of up-and-down rules for the sequential allocation of dose levels to subjects in a dose-response study. We show that an up-and-down design can be improved by using more information than the most recent response. For example, the k-in-a-row rule uses up to the k most recent responses. We introduce a new design, the Narayana rule, which uses a local estimate of the probability of toxicity calculated from all previous responses. For the Narayana rule, as the sample size gets large, the probability of assignment goes to zero for dose levels not among the two (or three) closest to the target. Different estimators of the target dose are compared. We find that the isotonic regression estimator is superior to other estimators for small to moderate sample sizes.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Anastasia Ivanova, Aliakbar Montazer-Haghighi, Sri Gopal Mohanty, Stephen D Durham. 2003-01-15. Improved up-and-down designs for phase I trials.. https://doi.org/10.1002/sim.1336

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact?

Much has been written recently about low productivity in the pharmaceutical industry and the high cost of drug development. Over a 10-year period ending in 2000, only approximately 11% of compounds tested in humans across 10 large pharmaceutical companies were eventually approved for marketing in the United States and/or Europe. Attrition was highest during phase II (62%) but still significant in phase III (45%) and at the time of registration (23%). Clearly, given the high cost and time required for clinical development, these late-stage failures are unsustainable.

Clinical Trials, Phase I as Topic↗

Transgenic probiotica as drug delivery systems: the golden bullet?

Functional human proteins are constitutively produced in genetically modified bacteria that survive on human mucosal surfaces, to the benefit of the host. The successful Phase I clinical trial with IL-10-producing Lactococcus lactis for Crohn's disease has opened new avenues for the use of transgenic bacteria as delivery vehicles. The major advantage of this novel strategy is the avoidance of systemic side effects associated with conventional therapies. This methodology opens up an alternative method for local delivery of therapeutic proteins to various mucosal tissues.

Clinical Trials, Phase I as Topic↗

Escalation, group and A + B designs for dose-finding trials.

In this paper, rules are given on how to construct escalation, A + B, and group designs for dose-finding trials. Operational characteristics of these designs are discussed and compared via simulations. Dose-finding designs for trials with ordinal toxicity outcome are considered.

Clinical Trials, Phase I as Topic↗